Table 1 |
|||
|
Demographic characteristics of the study subjects |
|||
| Characteristic |
SLE patients |
Healthy donors |
P |
|
|
|||
| Participants (n) |
108 |
46 |
- |
| Age (years) |
32.52 ± 11.97 |
32.5 ± 14.32 |
0.83 |
| Sex (n; female/male) |
96/12 |
40/6 |
0.62 |
| Onset age (years) |
27.14 ± 10.0 |
NA |
- |
| Disease duration (years) |
5.4 ± 4.13 |
NA |
- |
| SLEDAI-2K score (mean [range]) |
6 (3 to 8) |
NA |
- |
| Mean ESR (mm/hour) |
61.58 ± 24.03 |
NA |
- |
| Medical therapy (n) |
|||
| Prednisone >60 mg/day |
11 |
NA |
- |
| Prednisone 30 to 60 mg/day |
44 |
NA |
- |
| Prednisone 0 mg/day |
6 |
NA |
- |
| CTX |
35 |
NA |
- |
|
|
|||
| FIT4 relative expression |
37.84 ± 3.52 |
10.58 ± 2.64 |
0.00 |
|
|
|||
|
All patients were of Chinese ethnicity. Unless stated otherwise, values are expressed as mean ± standard deviation. CTX, cyclophosphamide; ESR, erythrocyte sedimentation rate; IFIT4, interferon-induced protein with tetratricopeptide repeats 4; NA, not applicable; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2,000. |
|||
|
Huang et al. Arthritis Research & Therapy 2008 10:R91 doi:10.1186/ar2475 |
|||
